Skip to content
Clinical Research Made Simple

Clinical Research Made Simple

Trusted Resource for Clinical Trials, Protocols & Progress

Tag: EMA risk-based inspection

EMA Inspection Metrics and Common Findings: A Detailed Regulatory Guide

Posted on May 10, 2025 digi By digi

EMA Inspection Metrics and Common Findings: A Detailed Regulatory Guide Understanding EMA Inspection Metrics and Key Observations in Pharma Audits The European Medicines Agency (EMA) plays a pivotal role in safeguarding public health by ensuring that pharmaceutical products in the EU meet strict quality, safety, and efficacy standards. One of its primary oversight mechanisms is…

Read More “EMA Inspection Metrics and Common Findings: A Detailed Regulatory Guide” »

EMA (European Medicines Agency) Guidelines, Regulatory Guidelines

EMA Inspection Metrics and Common Findings: A Regulatory Perspective

Posted on May 10, 2025 digi By digi

EMA Inspection Metrics and Common Findings: A Regulatory Perspective Key Trends and Findings from EMA Inspections Across the EU Regulatory Landscape The European Medicines Agency (EMA) plays a critical role in ensuring pharmaceutical products in the European Union adhere to the highest regulatory standards. One of its key functions is conducting regulatory inspections across GMP…

Read More “EMA Inspection Metrics and Common Findings: A Regulatory Perspective” »

EMA (European Medicines Agency) Guidelines, Regulatory Guidelines

Quick Guide

  • Clinical Trial Phases
    • Preclinical Studies
    • Phase 0 (Microdosing Studies)
    • Phase 1 (Safety and Dosage)
    • Phase 2 (Efficacy and Side Effects)
    • Phase 3 (Confirmation and Monitoring)
    • Phase 4 (Post-Marketing Surveillance)
  • Regulatory Guidelines
    • U.S. FDA Regulations
    • CDSCO (India) Guidelines
    • EMA (European Medicines Agency) Guidelines
    • PMDA (Japan) Guidelines
    • MHRA (UK) Guidelines
    • TGA (Australia) Guidelines
    • Health Canada Guidelines
    • WHO Guidelines
    • ICH Guidelines
    • ASEAN Guidelines
  • Clinical Trial Design and Protocol Development
    • Randomized Controlled Trials (RCTs)
    • Adaptive Trial Designs
    • Crossover Trials
    • Parallel Group Designs
    • Factorial Designs
    • Cluster Randomized Trials
    • Single-Arm Trials
    • Open-Label Studies
    • Blinded Studies (Single, Double, Triple)
    • Non-Inferiority and Equivalence Trials
    • Randomization Techniques in Crossover Trials
  • Good Clinical Practice (GCP) and Compliance
    • GCP Training Programs
    • ICH-GCP Compliance
    • GCP Violations and Audit Responses
    • Monitoring Plans
    • Investigator Responsibilities
    • Sponsor Responsibilities
    • Ethics Committee Roles

Menu

Recent Posts

  • Regulatory Requirements for Group Comparisons – Clinical Trial Design and Protocol Development
  • Cardiac Safety in Phase 1: QTc and Intensive ECG Monitoring
  • Endpoint Hierarchy Planning and Sensitivity Analyses in Phase 3 Trials: Ensuring Statistical Validity and Regulatory Confidence
  • Data Mining for Adverse Drug Reactions in Phase 4 Clinical Trials
  • Examples of Parallel Designs in Oncology Trials – Clinical Trial Design and Protocol Development

Copyright © 2025 Clinical Research Made Simple.

Powered by PressBook WordPress theme